These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 33973233)
41. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis. Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160 [TBL] [Abstract][Full Text] [Related]
42. Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas. Weide R; Heymanns J; Gores A; Köppler H Leuk Lymphoma; 2002 Feb; 43(2):327-31. PubMed ID: 11999564 [TBL] [Abstract][Full Text] [Related]
43. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. Dimou M; Papageorgiou SG; Stavroyianni N; Katodritou E; Tsirogianni M; Kalpadakis C; Banti A; Arapaki M; Iliakis T; Bouzani M; Verrou E; Spanoudakis E; Giannouli S; Marinakis T; Mandala E; Mparmparousi D; Sachanas S; Dalekou-Tsolakou M; Hatzimichael E; Vadikolia C; Violaki V; Poziopoulos C; Tsirkinidis P; Chatzileontiadou S; Vervessou E; Ximeri M; Sioni A; Konstantinidou P; Kyrtsonis MC; Siakantaris MP; Angelopoulou MK; Pappa V; Konstantopoulos K; Panayiotidis P; Vassilakopoulos TP Hematol Oncol; 2021 Aug; 39(3):336-348. PubMed ID: 33583077 [TBL] [Abstract][Full Text] [Related]
44. Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Howard DR; Munir T; Hockaday A; Rawstron AC; Collett L; Oughton JB; Allsup D; Bloor A; Phillips D; Hillmen P Trials; 2016 Sep; 17(1):456. PubMed ID: 27645620 [TBL] [Abstract][Full Text] [Related]
45. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma. Munakata W; Tobinai K Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460 [TBL] [Abstract][Full Text] [Related]
46. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A; Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758 [TBL] [Abstract][Full Text] [Related]
47. Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. Montillo M; Illés Á; Robak T; Pristupa AS; Wach M; Egyed M; Delgado J; Jurczak W; Morschhauser F; Schuh A; Eradat H; Shreay S; Barrientos JC; Zelenetz AD Health Qual Life Outcomes; 2019 Nov; 17(1):173. PubMed ID: 31729982 [TBL] [Abstract][Full Text] [Related]
48. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712 [TBL] [Abstract][Full Text] [Related]
49. Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma. Uchida M; Mori Y; Akiba K; Miyasaka M; Hirano T; Ikesue H; Yamaguchi Y; Takano A; Maegawa N; Shimomura Y; Hosohata K; Muroi N; Ishikawa T; Hashida T; Nakamura T Biol Pharm Bull; 2020 Oct; 43(10):1577-1582. PubMed ID: 32801282 [TBL] [Abstract][Full Text] [Related]
50. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W; Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739 [TBL] [Abstract][Full Text] [Related]
51. Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma. Plosker GL; Carter NJ Drugs; 2008; 68(18):2645-60. PubMed ID: 19093705 [TBL] [Abstract][Full Text] [Related]
52. Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design. Kumar A; Casulo C; Joffe E; Moskowitz C; Gerecitano J; Moskowitz A; Younes A; Drullinsky P; Drill E; Choma M; Grieve C; Joseph A; Laraque L; Schick D; Zelenetz A; Hamlin P Leuk Lymphoma; 2022 Dec; 63(12):2889-2896. PubMed ID: 35972020 [TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959 [TBL] [Abstract][Full Text] [Related]
54. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584 [TBL] [Abstract][Full Text] [Related]
55. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. Pott C; Sehn LH; Belada D; Gribben J; Hoster E; Kahl B; Kehden B; Nicolas-Virelizier E; Spielewoy N; Fingerle-Rowson G; Harbron C; Mundt K; Wassner-Fritsch E; Cheson BD Leukemia; 2020 Feb; 34(2):522-532. PubMed ID: 31462735 [TBL] [Abstract][Full Text] [Related]
56. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ; Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274 [TBL] [Abstract][Full Text] [Related]
57. CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma. Zinzani PL; Wang H; Feng J; Kim TM; Tao R; Zhang H; Fogliatto L; Maluquer Artigal C; Özcan M; Yanez E; Kim WS; Kirtbaya D; Kriachok I; Maciel F; Xue H; Bouabdallah K; Phelps C; Chaturvedi S; Weispfenning A; Morcos PN; Odongo F; Buvaylo V; Childs BH; Dreyling M; Matasar M; Ghione P Blood Adv; 2024 Sep; 8(18):4866-4876. PubMed ID: 39058951 [TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355 [TBL] [Abstract][Full Text] [Related]
59. Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20. Alrifai T; Grant Szymanski K; Venugopal P; Mahon B; Okwuosa T; Karmali R Chemotherapy; 2017; 62(2):140-146. PubMed ID: 27960150 [TBL] [Abstract][Full Text] [Related]
60. Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody Sarlo KM; Dixon BN; Ni A; Straus DJ Leuk Lymphoma; 2020 Feb; 61(2):364-369. PubMed ID: 31603363 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]